logo
Kansas launches new resources for small businesses, entrepreneurs

Kansas launches new resources for small businesses, entrepreneurs

Yahoo11-06-2025
Taylor Overton leads the new Kansas Department of Commerce Small Business Office. She spoke Tuesday at the Tee Box in Topeka. (Morgan Chilson/Kansas Reflector)
TOPEKA — Tools for small business owners are now available through the Kansas Small Business Office, leaders with the Kansas Department of Commerce announced Tuesday while highlighting the need to encourage entrepreneurship and business development in the state.
Connect KS, a resource website that will answer questions of small business owners and help them find resources in their part of the state, is part of the SBO, said Taylor Overton, who heads up the new office.
The resources were announced at an event at the Tee Box in downtown Topeka that drew entrepreneurs from across the state to share the importance of finding programs and information to help them succeed. In addition, many spoke about being part of a Kansas delegation recently at the Global Entrepreneurship Congress in Indiana.
'One of the reasons why this is so important is that new businesses under five years old create the most net new jobs in our economy,' said Jason Grill, with Right to Start, a nonprofit organization that advocates for small businesses. 'They also grow GDP, and they increase lifetime incomes. They increase community wealth, very much so, in lifetime incomes, they diversify our goods and services in our communities, and they fight inequality and poverty.'
Grill told about 50 people gathered that for every 1% increase in entrepreneurship in a community, there is a 2% decrease in poverty.
Joshua Jefferson, deputy secretary of business development at the commerce department, said the coordination of resources throughout the state is key to the new initiatives.
'We're here to commit to the work of a new era in small business support here in Kansas,' he said. 'The COVID 19 pandemic exposed that the Kansas Department of Commerce was not doing enough for small businesses in the state of Kansas. In the wake of a once-in-a-century economic crisis, we examined the way that the agency was working, and in the process, we discovered that we really weren't supporting small business as much as we could, or that we should.'
Jefferson said the creation of the SBO, along with resources like Connect KS, was the culmination of those efforts to change the state's support network.
'We can do more, and we will do more,' he said.
He outlined resources included in the SBO and stressed that part of the task has been making them easier to navigate and accessible to all Kansans.
'By creating a coordinated statewide hub for entrepreneurs at every stage, we're coordinating key resources and creating centralized points of contact for entrepreneurs who are navigating the tough work of business development certifications, permitting access to capital, mentorships and much, much more,' he said.
Much of the work of the SBO is connecting people with opportunity, and Overton said she was excited to take a Kansas delegation to the global congress to network with people from around the world.
Wichita business owner Kristin Kienzle, who attended the Global Entrepreneurship Congress in Indiana, said she is learning about creating a successful franchising model that can be replicated nationwide as she explores opportunities to expand into Oklahoma.
Kienzle, who owns Utopia Modern Salon Suites, grew her unique approach to offering salon services from one site to three in Wichita, with more on the way.
'I learned some tactical things. I learned some inspirational things and then I also just kind of learned some things about myself,' she said.
Being with other entrepreneurs helped her realize how little people understand about what it takes to start a business and manage all the risks.
'As an entrepreneur, we just do what we do,' she said. 'So being in the room on a grand stage with all these people who have done great things, everyone from Mark Cuban down to the guy who started this business six weeks ago, and everything in between was just so it just made me realize, wow, these people, and this is a really unique crowd.'
Trademark attorney Julie Grabbe, of Hays, said meeting people from other countries was valuable.
'I'm in west Kansas, so we're in a different situation than a lot of the more metropolitan cities,' she said. 'But commerce is very important to us. We want to be able to keep our young talent. We want to keep growing our cities. We want it to be a vibrant place to live. I think one of the ways to do that is really to have the support of the state to go out and do these kinds of things and get these ideas.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

Yahoo

time2 hours ago

  • Yahoo

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

WATERTOWN, Mass., August 20, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). This enforcement action targets Pfizer's activities in the 18 countries of the European Union that are presently participating in the UPC. The European Patent Office's recent grant of the '265 Patent to Enanta was published in the European Patent Bulletin today. The '265 Patent is based on Enanta's July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists. The '265 Patent is the European counterpart of U.S. Patent No. 11,358,953 (the '953 Patent) involved in ongoing U.S. litigation between Enanta and Pfizer Inc. Under UPC procedures, a hearing on the infringement action is expected to occur within the UPC's published 12-month target, with the decision rendered within weeks thereafter. If the UPC determines there has been infringement, subsequent proceedings would be required to determine damages. All timelines remain subject to potential rights of appeal and other customary proceedings in European patent litigation. About Enanta Pharmaceuticals, is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. Forward Looking Statements DisclaimerThis press release contains forward-looking statements, including statements with respect to Enanta's filing in the UPC of a suit against Pfizer Inc. and certain of its subsidiaries seeking a determination of liability for use and infringement of Enanta's patent and Enanta's expectations with respect to any further action with respect to such proceedings. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including those covering one or more of its product candidates, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta's senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta's reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in "Risk Factors" in Enanta's Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law. View source version on Contacts Media and Investor Contact Jennifer Viera617-744-3848jviera@ Sign in to access your portfolio

For Kansas GOP, Trump and his ‘beautiful' bill parallel Brownback's poisonous tax ‘experiment'
For Kansas GOP, Trump and his ‘beautiful' bill parallel Brownback's poisonous tax ‘experiment'

Yahoo

time3 hours ago

  • Yahoo

For Kansas GOP, Trump and his ‘beautiful' bill parallel Brownback's poisonous tax ‘experiment'

President Donald Trump holds up the "big, beautiful bill" that was signed into law as during a Fourth of July military family picnic on the South Lawn of the White House on July 4, 2025 in Washington, D.C. (Photo by Alex Brandon - Pool/Getty Images) Within a year, Kansans will be voting to elect a new governor and fill a U.S. Senate seat, plus four congressional seats, among elections for other offices. Candidates are already announcing for office, and campaigns are getting underway. Most Republican candidates are fawning at the feet of President Donald Trump. The groveling of these sycophants may be misplaced as Kansas voters recall the toxic remains of Gov. Sam Brownback's infamous tax experiment, initiated in 2012 and abandoned in 2017 after five years of unfair taxes, deficit spending, and record debt. Trump's 'one big, beautiful bill' has followed a path that parallels Brownback's tax experiment and may experience the same result. After six months in office, available evidence suggests that Trump and the bill may become political liabilities for the grovelers. Take a look at the parallels. Both Brownback and Trump chose partisanship rather than seeking common ground, and as a result, political liability falls entirely on Republicans. Democrats were shut out of decisions. Both partisan plans had to be forced through with brazen arm-twisting. When Brownback's tax bill stalled over disagreements between the legislative chambers, the governor double-crossed state Senate leadership and signed a flawed bill intended for negotiation. Brownback later stood aside as the Kansas Chamber of Commerce PAC effectively purged state senators of the governor's party who opposed the policy. Trump issued multiple threats of primary challenges targeted at resistant Republicans to bring them into line on the 'big, beautiful bill.' One senator who balked fell victim to the pressure and announced he would not seek reelection. Both Brownback's tax experiment and Trump's bill were Koch inspired. Brownback sought the advice of Arthur Laffer, a Koch-sponsored tax-cut guru, and shortly thereafter embraced 'a real live experiment' to eliminate state income taxes. Koch and a handful of well-heeled donors underwrote a million-dollar campaign through the Chamber PAC to elect legislators willing to do their bidding. Their campaign succeeded. Americans for Prosperity, a Koch political network, called early for Trump to renew and deepen tax cuts and launched a multimillion-dollar campaign to 'turn up the heat' on Congress for quick passage. Both Brownback's tax experiment and Trump's 'big, beautiful bill' had common intent: Benefiting the wealthy while costing everyone else. Brownback's experiment tilted the tax burden from rich to poor; it further exempted 330,000 businesses from the income tax and promised the eventual elimination of the tax. Trump's law gives households with incomes in the top 10% a break of $12,000 per year while those in the bottom 10% pay an additional $1,600, according to estimates by the Congressional Budget Office. The top 1% are the prime beneficiaries. Additionally, both Brownback and Trump coupled tax cuts for the rich with measures undermining aid to the needy. Brownback restricted eligibility for income support and food assistance and blocked the expansion of Medicaid. The budget office estimates the 'big, beautiful bill' will slash more than $1 trillion in spending from Medicaid and food assistance for the next 10 years, primarily by restricting eligibility for aid. Ten to 12 million will be cut from Medicaid, and those qualified for food assistance will fall as well. Brownback's experiment created red ink as far as the eye could see, and Trump's plan will do the same. The Kansas Legislative Research Department projected soaring deficits from Brownback's tax experiment, amounting to $2.5 billion in the first five years. Even after a sales tax increase, the depletion of state balances and the diversion of highway funds, the state faced a mid-year deficit of $300 million in 2017. The Congressional Budget Office estimates Trump's law will increase the deficit to $3.4 trillion over the next 10 years and add $4 trillion to the national debt when interest payments are taken into account. Even so, the rhetoric of both Brownback and Trump soared: Brownback claimed his experiment would provide 'a glide path to zero' for state income taxes. And further: 'Look out Texas, here comes Kansas!' Trump declares the 'big, beautiful bill' would 'make this country into a rocket ship. It's going to be really great. … We'll have growth in record numbers.' After five years of unbalanced budgeting, one-sided taxing, and unprecedented borrowing, Kansas voters had seen enough of Brownback's experiment. The governor's approval ratings steadily sank to the lowest in the nation among governors. In 2016, voters ousted Brownback's legislative allies and elected a bipartisan legislative coalition that expeditiously abandoned the experiment and restored sanity to state finances. In Trump's first six months, his disapproval ratings have bumped up by 10 percentage points, well above comparable figures for Biden, Obama, and George W. Bush. Recent polling indicates 55% disapproval of the 'big, beautiful bill,' compared with 29% approval. In the upcoming election contests, Kansans will have the opportunity to query incumbents about their choices: shoddy partisan tactics over bipartisanship. Sponsorship by Koch. Support for taxes that benefit the rich and ditch the poor. Votes that swamped the state and nation in a sea of red ink. We now what they did back in 2016. We'll see what they decide in 2026. H. Edward Flentje is a professor emeritus at Wichita State University and formerly was director and professor in the Hugo Wall School of Public Affairs at the university. He has written and edited numerous publications, including most recently co-writing and co-editing 'Reform and Reaction: The Arc of Kansas Politics.' Through its opinion section, Kansas Reflector works to amplify the voices of people who are affected by public policies or excluded from public debate. Find information, including how to submit your own commentary, here.

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ('Stratus')
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ('Stratus')

Yahoo

time2 days ago

  • Yahoo

Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG ('Stratus')

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA® (pemivibart) against XFG Centers for Disease Control data and wastewater surveillance data indicate XFG variant appears to be driving a growing wave of COVID-19 in America VYD2311 in vitro neutralization data demonstrate similarly consistent and highly potent results against XFG Similar new, positive in vitro neutralization data for pemivibart and VYD2311 against other SARS-CoV-2 viruses currently circulating in the U.S. (NB.1.8.1 ('Nimbus') and LF.7.9, as well as LP.8.1) affirm Invivyd's unique technology, reflect consistently stable target epitopes, and indicate ongoing, complete coverage of any tested, relevant SARS-CoV-2 variant by Invivyd's investigational monoclonal antibodies; no non-responsive viruses identified or anticipated Data to be provided to U.S. FDA imminently, with anticipated inclusion in PEMGARDA Fact Sheet for Healthcare Providers WALTHAM, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA® (pemivibart) against the currently dominant and growing XFG variant of SARS-CoV-2. Notably, and consistent with all dominant variants for the past three years, XFG did not generate any meaningful change to the in vitro neutralization activity of pemivibart or VYD2311, the company's next generation COVID-19 monoclonal antibody (mAb) candidate, as the epitopes targeted by pemivibart and VYD2311 remain structurally intact. PEMGARDA (pemivibart) is authorized by the U.S. Food and Drug Administration (FDA) for pre-exposure prophylaxis of COVID-19 in certain immunocompromised patients. Currently, the level of COVID-19 viral activity detected in wastewater in 12 states is reported as high or very high levels as of early August, and the U.S. Centers for Disease Control and Prevention (CDC) estimates that COVID-19 infections are growing or likely growing in 34 states and declining in zero states, according to forecasting models. Further, the company estimates that every clinical variant reported in the CDC COVID Data Tracker since the Omicron BA.2 lineage has been susceptible to pemivibart, even if untested, due to the consistent structural integrity of the epitope targeted by pemivibart. Therefore, Invivyd anticipates continued meaningful clinical activity for pemivibart for the foreseeable future if the epitope pemivibart targets remains intact. 'COVID-19 activity is once again on the rise across much of the United States, with wastewater data and forecasting models pointing to sustained growth in infections. Against this backdrop, we are pleased but not surprised that pemivibart has continued to demonstrate neutralizing activity against the currently dominant XFG variant, and we look forward to rapidly advancing our next generation antibody VYD2311 which has shown similar in vitro neutralization results at much higher potency. The demonstrated stability of the epitopes our monoclonal antibodies target across SARS-CoV-2 evolution underscores the strength of our molecular design strategy and our capability in creating high-barrier-to-resistance medicines,' said Robert Allen, Ph.D., Chief Scientific Officer of Invivyd. 'For people whose immune systems may not get enough protection from vaccines such as those on immunosuppressive therapies and those undergoing cancer treatment, each new COVID-19 wave can create additional challenges and disrupt care,' commented Tim Lee, Chief Commercial Officer of Invivyd. 'Pemivibart has shown extraordinary continuing in vitro neutralization activity against SARS-CoV-2 over now several years, and our next-generation antibody VYD2311 represents another hopeful step toward more scalable protection with a more patient-friendly route of administration.' Data showing continued in vitro neutralizing activity of PEMGARDA® (pemivibart) against XFG and other circulating viruses will be provided to the FDA imminently, with anticipated inclusion in the PEMGARDA Fact Sheet for Healthcare Providers. About PEMGARDA PEMGARDA® (pemivibart) is a half-life extended investigational monoclonal antibody (mAb). PEMGARDA was engineered from adintrevimab, Invivyd's investigational mAb that has a robust safety data package and provided evidence of clinical efficacy in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. PEMGARDA has demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants, including JN.1, KP.3.1.1, XEC and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby inhibiting virus attachment to the human ACE2 receptor on host cells. PEMGARDA (pemivibart) injection (4500 mg), for intravenous use is an investigational mAb that has not been approved, but has been authorized for emergency use by the U.S. FDA under an EUA for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg) who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. PEMGARDA is not authorized for use for treatment of COVID-19, treatment of Long COVID, or post-exposure prophylaxis of COVID-19. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccinations, should receive COVID-19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. Anaphylaxis has been observed with PEMGARDA and the PEMGARDA Fact Sheet for Healthcare Providers includes a boxed warning for anaphylaxis. The most common adverse reactions included systemic infusion-related reactions and hypersensitivity reactions, local infusion site reactions, and infusion site infiltration or extravasation. For additional information, please see the PEMGARDA full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning. To support the EUA for PEMGARDA, an immunobridging approach was used to determine if PEMGARDA may be effective for pre-exposure prophylaxis of COVID-19. Immunobridging is based on the serum virus neutralizing titer-efficacy relationships identified with other neutralizing human mAbs against SARS-CoV-2. This includes adintrevimab, the parent mAb of pemivibart, and other mAbs that were previously authorized for EUA. There are limitations of the data supporting the benefits of PEMGARDA. Evidence of clinical efficacy for other neutralizing human mAbs against SARS-CoV-2 was based on different populations and SARS-CoV-2 variants that are no longer circulating. Further, the variability associated with cell-based EC50 value determinations, along with limitations related to pharmacokinetic data and efficacy estimates for the mAbs in prior clinical trials, impact the ability to precisely estimate protective titer ranges. Additionally, certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA, and PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. The emergency use of PEMGARDA is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner. PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90%, based on available information including variant susceptibility to PEMGARDA and national variant frequencies. About VYD2311 VYD2311 is a novel monoclonal antibody (mAb) candidate being developed for COVID-19 to continue to address the urgent need for new prophylactic and therapeutic options. The pharmacokinetic profile and antiviral potency of VYD2311 may offer the ability to deliver clinically meaningful titer levels through more patient-friendly means such as an intramuscular route of administration. VYD2311 was engineered using Invivyd's proprietary integrated technology platform and is the product of serial molecular evolution designed to generate an antibody optimized for neutralizing contemporary virus lineages. VYD2311 leverages the same antibody backbone as pemivibart, Invivyd's investigational mAb granted emergency use authorization in the U.S. for the pre-exposure prophylaxis (PrEP) of symptomatic COVID-19 in certain immunocompromised patients, and adintrevimab, Invivyd's investigational mAb that has a robust safety data package and demonstrated clinically meaningful results in global Phase 2/3 clinical trials for the prevention and treatment of COVID-19. About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit to learn more. Trademarks are the property of their respective owners. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'anticipates,' 'believes,' 'could,' 'expects,' 'estimates,' 'hypothesizes,' 'intends,' 'potential,' 'predicts' 'projects,' and 'future' or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the company's ongoing research and development activities, as well as future potential research and development efforts; the ongoing in vitro neutralizing activity of PEMGARDA and VYD2311 against dominant SARS-CoV-2 variants; anticipated update to the PEMGARDA Fact Sheet for Healthcare Providers; expectations regarding the COVID-19 landscape and growing U.S. COVID-19 infections; expectations regarding the neutralization activity of pemivibart and VYD2311 for the foreseeable future, and beliefs about the stability of the epitope targeted by pemivibart and VYD2311; expectations about the strength of Invivyd's molecular design strategy and its capability in creating high-barrier-to-resistance medicines; the potential of PEMGARDA as a mAb for pre-exposure prophylaxis (prevention) of COVID-19 in certain immunocompromised persons; the potential of VYD2311 as a novel mAb candidate that may be able to deliver clinically meaningful titer levels through more patient-friendly means; the company's devotion to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2; and other statements that are not historical fact. The company may not actually achieve the plans, intentions or expectations disclosed in the company's forward-looking statements and you should not place undue reliance on the company's forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing, progress and results of the company's discovery, preclinical and clinical development activities; the risk that results of nonclinical studies or clinical trials may not be predictive of future results, and interim data are subject to further analysis; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of the company's product candidates based on neutralizing activity in nonclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; the company's reliance on third parties with respect to virus assay creation and product candidate testing; variability of results in models and methods used to predict activity against SARS-CoV-2 variants; whether the epitope that pemivibart and VYD2311 targets remains structurally intact; whether the company's product candidates are able to demonstrate and sustain neutralizing activity against major SARS-CoV-2 variants, particularly in the face of viral evolution; whether U.S. COVID-19 infections grow as estimated by forecasting models; how long the EUA granted by the FDA for PEMGARDA will remain in effect and whether the EUA is revised or revoked by the FDA; the success of the company's in-house sales force, and the company's ability to maintain and expand sales, marketing and distribution capabilities to successfully commercialize PEMGARDA; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways for authorization or approval of the company's product candidates; the ability to maintain a continued acceptable safety, tolerability and efficacy profile of any product candidate following regulatory authorization or approval; changes in the regulatory environment; the outcome of the company's engagement with regulators; uncertainties related to the regulatory authorization or approval process, and available development and regulatory pathways; changes in expected or existing competition; the complexities of manufacturing mAb therapies; the company's ability to continue as a going concern; and whether the company has adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause the company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading 'Risk Factors' in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, each as filed with the Securities and Exchange Commission (SEC), and in the company's other filings with the SEC, and in its future reports to be filed with the SEC and available at Forward-looking statements contained in this press release are made as of this date, and Invivyd undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Contacts: Media Relations(781) 208-1747media@ Relations(781) 208-1747investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store